Plain-English translation of NCT04887792 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether , a medication that has been used safely for over 50 years to treat other brain conditions, might help people with schizophrenia who haven't responded well to standard antipsychotic drugs. Researchers found in earlier studies that adding this medication to regular antipsychotic treatment improved symptoms in some patients. This trial will confirm whether this treatment works and is safe for more people.
About 30 to 40% of people with schizophrenia don't get much relief from current antipsychotic medications, and the only other reliable option (clozapine) can cause serious side effects. This study exists to find a safer, additional treatment option for people whose symptoms remain difficult to control.
You likely qualify if…
You likely don't qualify if…
You would continue taking your regular antipsychotic medication and receive either the study medication or a placebo (inactive pill) in identical capsules so neither you nor the researchers know which one you're taking. The study is designed as a crossover trial, meaning you may receive both the treatment and placebo at different times. You would attend study visits where your symptoms and any side effects are monitored, and the study team would track how you respond to the treatment over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
India
Phase
Safety & dosing / Early efficacy
Sponsor
Vishwajit Nimgaonkar, MD PhD
Collaborators
Stanley Medical Research Institute
Enrollment target
~60 participants
Started
February 2022
Primary completion
June 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vishwajit L Nimgaonkar, M.D., Ph.D.
University of Pittsburgh
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.